港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

轩竹生物-B

63.600

-0.350-0.55%

成交量：33.68万

成交额：2,124.75万

市值：329.41亿

市盈率：-47.11

高：63.900

开：63.900

低：62.500

收：63.950

52周最高：72.000

52周最低：23.820

股本：5.18亿

香港流通股本：1.61亿

量比：0.99

换手率：0.21%

股息：- -

股息率：- -

每股收益(LYR):-1.350

净资产收益率：--

总资产收益率：--

市净率：35.62

市盈率(LYR):-47.11

市销率: 942.78

数据加载中...

总览公司新闻资讯公告

轩竹生物-B(02575)就建议实施H股全流通向中国证监会备案

轩竹生物-B(02575)建议实施H股全流通

轩竹生物-B11月14日遭主力抛售32.6万元

轩竹生物-B11月11日遭主力抛售556.8万元

荣誉 | 轩竹生物荣膺中国证券报“成长价值金牛奖”

轩竹生物-B11月06日主力净流入203.0万元散户资金抛售

港股异动 | 轩竹生物-B(02575)尾盘涨超9%创上市新高 NG-350A此前获授美国FDA快速通道资格认定

轩竹生物-B11月03日获主力加仓285.2万元

【IPO月报】10月IPO赚钱效应继续：金叶超购逾万倍长风药业首日可赚万七

轩竹生物－Ｂ股价大涨5.03% 吡洛西利治疗乳腺癌临床III期研究数据于ESMO公布

直击国谈第二日：肿瘤、慢病领域重磅药开谈！

猛犸资本局

轩竹生物-B10月31日获主力加仓401.0万元

轩竹生物-B(02575)：NG-350A获授美国FDA快速通道资格认定

轩竹生物-B再飙逾8%，股价创上市以来新高！该股上市至今累计上涨逾450%

老虎资讯综合

轩竹生物-B(02575)涨5.2% 上市两周股价翻倍吡洛西利一线治疗临床III期展现出良好的疗效性

四环医药走出阵痛

医药生物行业跟踪周报：2025ESMO中国之声闪耀全球 PD1双抗与ADC成为全球焦点

一周港股牛熊榜 | 周内飙升75%！次新股轩竹生物上市累升逾400%；老铺黄金、泡泡玛特周跌超16%

老虎资讯综合

轩竹生物-B10月24日主力净流入124.5万元散户资金抛售

大涨456%！创新药万绿丛中，这家“独红”？

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02575/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02575","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"轩竹生物-B","latestPrice":63.6,"timestamp":1763366893772,"preClose":63.95,"halted":0,"volume":336804,"delay":0,"floatShares":160701996,"shares":517947790,"eps":-1.3501214787117437,"marketStatus":"已收盘","change":-0.35,"latestTime":"11-17 16:08:13","open":63.9,"high":63.9,"low":62.5,"amount":21247494,"amplitude":0.021892,"askPrice":63.65,"askSize":2500,"bidPrice":63.2,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-1.3499563798692464,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":5,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":63.95,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":0.994732,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","floatShares":160701996,"roa":"--","roe":"--","lyrEps":-1.350121,"volumeRatio":0.994732,"shares":517947790,"dividePrice":0,"high":63.9,"amplitude":0.021892,"preClose":63.95,"low":62.5,"week52Low":23.82,"pbRate":"35.62","psRate":"942.78","week52High":72,"institutionHeld":0,"latestPrice":63.6,"committee":-0.666667,"eps":-1.3501214787117437,"divideRate":0,"volume":336804,"delay":0,"ttmEps":-1.3499563798692464,"open":63.9,"prevYearClose":11.6,"prevWeekClose":63.95,"prevMonthClose":63.6,"prevQuarterClose":11.6,"fiveDayClose":66.2,"twentyDayClose":33.9,"sixtyDayClose":11.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02575\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02575\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02575\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02575\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02575","date":"2025-11-14","current":-46.796344,"percent":0.428571,"low":-59.374256,"twenty":-55.639174,"median":-54.1994,"eighty":-41.200731,"high":-22.444691,"avg":-48.666426,"sd":11.257814,"marketCap":33122761170},"quantilePoints":[{"date":"2025-10-17","current":-28.93414,"twenty":-27.261252,"median":-24.751919,"eighty":-23.367582,"marketCap":17558430081},{"date":"2025-10-24","current":-50.850969,"twenty":-50.816841,"median":-33.923646,"eighty":-26.424807,"marketCap":30869688284},{"date":"2025-10-31","current":-54.182971,"twenty":-53.663557,"median":-50.808309,"eighty":-28.95487,"marketCap":32941479444},{"date":"2025-11-07","current":-55.367666,"twenty":-55.639174,"median":-53.630543,"eighty":-30.992132,"marketCap":33640708960},{"date":"2025-11-14","current":-54.36116,"twenty":-55.639174,"median":-54.1994,"eighty":-41.200731,"marketCap":33122761170}],"updateTime":1763353038723},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02575\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2584648040","title":"轩竹生物-B(02575)就建议实施H股全流通向中国证监会备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2584648040","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584648040?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 16:32","pubTimestamp":1763368334,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B(02575)公布，于 2025年 11月 17日，公司已向中国证监会提交备案申请，内容有关建议实施H股全流通，以按一对一基准将合共357,245,794股未上市股份转换为H股。待完成所有备案规定(包括向中国证监会备案)并获得所有相关批准(包括联交所批准转换及上市)并遵守所有适用法律、法规及规则后，357,245,794股未上市股份将转换为357,245,794股H股，并将于联交所上市及买卖。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575"],"gpt_icon":0},{"id":"2583575835","title":"轩竹生物-B(02575)建议实施H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2583575835","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583575835?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 16:32","pubTimestamp":1763109131,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B(02575)公布，于 2025年11月14日，董事会经考虑及批准实施H股全流通的建议，即将公司六名股东持有的357,245,794股公司未上市股份转换为公司H股(占公司于本公告日期已发行股份总数约68.9733%)。待取得所有相关批准(包括向中国证监会存档)并遵守所有适用法律、法规及规则后，357,245,794股未上市股份将转换为H股，而公司亦将向联交所申请批准该等H股于联交所主板上市及买卖。于本公告日期，公司尚未向中国证监会申请H股全流通。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575"],"gpt_icon":0},{"id":"2583509577","title":"轩竹生物-B11月14日遭主力抛售32.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583509577","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583509577?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 16:15","pubTimestamp":1763108122,"startTime":"0","endTime":"0","summary":"11月14日, 轩竹生物-B股价跌0.23%，报收63.95元，成交金额2318.9万元，换手率0.23%，振幅2.81%，量比0.92。轩竹生物-B今日主力资金净流出32.6万元，连续6日净流出，上一交易日主力净流出332.5万元。该股近5个交易日下跌2.39%，主力资金累计净流出1402.8万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入4820.8万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114161647a4a10c35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114161647a4a10c35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0},{"id":"2582352318","title":"轩竹生物-B11月11日遭主力抛售556.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582352318","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582352318?lang=zh_cn&edition=fundamental","pubTime":"2025-11-11 16:15","pubTimestamp":1762848954,"startTime":"0","endTime":"0","summary":"11月11日, 轩竹生物-B股价跌2.34%，报收64.65元，成交金额2105.2万元，换手率0.20%，振幅3.55%，量比0.79。轩竹生物-B今日主力资金净流出556.8万元，连续3日净流出，上一交易日主力净流出138.3万元。该股近5个交易日下跌0.92%，主力资金累计净流出500.1万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入6352.1万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111116214494fd37ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111116214494fd37ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0},{"id":"2582335618","title":"荣誉 | 轩竹生物荣膺中国证券报“成长价值金牛奖”","url":"https://stock-news.laohu8.com/highlight/detail?id=2582335618","media":"轩竹生物","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582335618?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 16:39","pubTimestamp":1762763983,"startTime":"0","endTime":"0","summary":"11月8日，由中国证券报主办、新华社新闻信息中心承办的“2025厦门产业发展大会暨金圆集团杯·上市公司（港股）金牛奖颁奖典礼”于厦门成功举行。本次大会上，轩竹生物科技股份有限公司凭借在生物医药领域突出的创新研发能力、强劲的成长潜力与广阔的发展前景，从一众入围企业中脱颖而出，荣膺“成长价值金牛奖”。此次荣获“成长价值金牛奖”，正是对公司创新研发实力、全链条开发能力与高质量成长潜力的最佳印证。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110164155a6ef0747&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110164155a6ef0747&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0},{"id":"2581097115","title":"轩竹生物-B11月06日主力净流入203.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2581097115","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581097115?lang=zh_cn&edition=fundamental","pubTime":"2025-11-06 16:15","pubTimestamp":1762416947,"startTime":"0","endTime":"0","summary":"11月06日, 轩竹生物-B股价涨6.34%，报收69.65元，成交金额4123.2万元，换手率0.38%，振幅9.92%，量比1.69。轩竹生物-B今日主力资金净流入203.0万元，上一交易日主力净流出0万元。该股近5个交易日上涨10.56%，主力资金累计净流入889.2万元；近20日主力资金累计净流入7055.3万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110616203394f2d684&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110616203394f2d684&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0},{"id":"2581056710","title":"港股异动 | 轩竹生物-B(02575)尾盘涨超9%创上市新高 NG-350A此前获授美国FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2581056710","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581056710?lang=zh_cn&edition=fundamental","pubTime":"2025-11-06 15:52","pubTimestamp":1762415537,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B尾盘涨超9%，高见71.6港元创上市新高。消息面上，轩竹生物上月底宣布，集团从临床阶段肿瘤公司Akamis授权引进的产品NG-350A获得美国食品药品监督管理局授予快速通道资格，用于治疗错配修复功能完整的局部晚期直肠癌。国家医保局此前公布的通过初步形式审查的名单显示，轩竹生物的吡洛西利片已成功入围，对于吡洛西利片而言，能否最终纳入国家医保目录同样至关重要。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4017","02575","NG"],"gpt_icon":0},{"id":"2580291016","title":"轩竹生物-B11月03日获主力加仓285.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2580291016","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580291016?lang=zh_cn&edition=fundamental","pubTime":"2025-11-03 16:15","pubTimestamp":1762157738,"startTime":"0","endTime":"0","summary":"11月03日, 轩竹生物-B股价涨4.32%，报收66.35元，成交金额2200.1万元，换手率0.21%，振幅9.43%，量比0.42。轩竹生物-B今日主力资金净流入285.2万元，连续4日净流入，上一交易日主力净流入401.0万元。该股近5个交易日上涨11.58%，主力资金累计净流入979.0万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入6852.2万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251103161851a6dd5f6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251103161851a6dd5f6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0},{"id":"2580163264","title":"【IPO月报】10月IPO赚钱效应继续：金叶超购逾万倍 长风药业首日可赚万七","url":"https://stock-news.laohu8.com/highlight/detail?id=2580163264","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580163264?lang=zh_cn&edition=fundamental","pubTime":"2025-11-03 16:09","pubTimestamp":1762157343,"startTime":"0","endTime":"0","summary":"10月新股IPO数量继续保持高位，认购情绪高涨，金叶国际集团认购倍数超万倍，同时，多只新股上市首日表现亮眼，市场交投活跃度显著提升，为香港资本市场注入新活力。业绩表现方面，10月30日，公司发布前三季度业绩，归属于上市公司股东的净利润约71.36亿元，同比增长46.58%;基本每股收益0.8455元。不过需要注意的是，长风药业在上市后未能延续首日的强劲走势，股价出现接连数日的回吐行情。目前，已获上市委员会批准，待上市数量为19家。","market":"other","thumbnail":"https://static.szfiu.com/news/20220324/YzUxYTE2NDgwOTA4NjcwODA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/YzUxYTE2NDgwOTA4NjcwODA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1968923","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00638","08549","BK1148","BK1191","BK1214","02637","BK1149","06031","06687","BK1171","BK1240","02575","02650","BK1109","02670","02652"],"gpt_icon":1},{"id":"2580294839","title":"轩竹生物－Ｂ股价大涨5.03% 吡洛西利治疗乳腺癌临床III期研究数据于ESMO公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2580294839","media":"港美通","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580294839?lang=zh_cn&edition=fundamental","pubTime":"2025-11-03 15:11","pubTimestamp":1762153911,"startTime":"0","endTime":"0","summary":"11月3日14:53，轩竹生物－Ｂ(02575)股价大幅上涨5.03%。该股报66.800港元，最高报66.800港元，最低报62.000港元，成交量19.27万股，成交额1237.43万港元。消息面上，轩竹生物近日发布公告称，公司在2025年欧洲肿瘤内科学会（ESMO）上以壁报的形式展示了吡洛西利联合来曲唑或阿那曲唑在HR+/HER2-（激素受体阳性、人表皮生长因子受体2阴性）晚期乳腺癌一线治疗的临床Ⅲ期（BRIGHT-3）的期中分析结果。据悉，轩竹生物科技股份有限公司是一家中国生物制药公司，公司有超过十种药物资产在积极开发中，涵盖消化系统疾病、肿瘤和NASH。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251103152010a6dd39e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251103152010a6dd39e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0},{"id":"2580490245","title":"直击国谈第二日：肿瘤、慢病领域重磅药开谈！","url":"https://stock-news.laohu8.com/highlight/detail?id=2580490245","media":"猛犸资本局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580490245?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 22:09","pubTimestamp":1761919791,"startTime":"0","endTime":"0","summary":"10月31日是2025年国家医保谈判的第2日，各大医药企业代表在早上8点前就已排队进入全国人大会议中心。时代周报记者从全国人大会议中心西门现场了解到，第二天谈判主要涉及肿瘤、慢病等重大疾病领域，谈判节奏明显慢于前一天。时代周报记者从场外等候药企代表的交谈中得知，今天谈判药品包括抗肿瘤和慢病类药物，参与谈判多为肿瘤企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031230619a6d928b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031230619a6d928b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","LU0359202008.SGD","LU0359201885.HKD","LU0359201612.USD","LU2543165471.USD","BK1161","BK1191","02575","02616","06978","01276","LU1023057109.AUD"],"gpt_icon":0},{"id":"2580490217","title":"轩竹生物-B10月31日获主力加仓401.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2580490217","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580490217?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 16:15","pubTimestamp":1761898554,"startTime":"0","endTime":"0","summary":"10月31日, 轩竹生物-B股价涨0.95%，报收63.60元，成交金额3214.3万元，换手率0.31%，振幅8.25%，量比0.44。轩竹生物-B今日主力资金净流入401.0万元，连续3日净流入，上一交易日主力净流入216.8万元。该股近5个交易日上涨6.39%，主力资金累计净流入818.4万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入6567.0万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103116223794e71a36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103116223794e71a36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0},{"id":"2578393801","title":"轩竹生物-B(02575)：NG-350A获授美国FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2578393801","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578393801?lang=zh_cn&edition=fundamental","pubTime":"2025-10-28 16:35","pubTimestamp":1761640501,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B(02575)发布公告，集团从临床阶段肿瘤公司AkamisBioLtd.(Akamis)授权引进的产品NG-350A获得美国食品药品监督管理局(FDA)授予快速通道资格(FastTrackdesignation)，用于治疗错配修复功能完整(pMMR)的局部晚期直肠癌(LARC)。集团拥有NG-350A产品的大中华区开发、生产与商业化的独家权利。FDA快速通道资格认定是一种加速开发和审批潜在药物的方法。被授予快速通道资格认定的药物旨在治疗严重疾病并解决未满足的医疗需求，其可能是针对特定疾病的首个疗法，或与现有疗法相比更具显着临床优势，或提高现有疗法的安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1361225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4017","02575","NG"],"gpt_icon":0},{"id":"1126538132","title":"轩竹生物-B再飙逾8%，股价创上市以来新高！该股上市至今累计上涨逾450%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126538132","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126538132?lang=zh_cn&edition=fundamental","pubTime":"2025-10-27 13:17","pubTimestamp":1761542266,"startTime":"0","endTime":"0","summary":"次新股$轩竹生物-B(02575)$再飙逾8%，股价站上65港元/股，创上市以来新高！该股上市至今累计上涨逾450%。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4b523e98237f91adae828bb001360c45","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":0},{"id":"2578304660","title":"轩竹生物-B(02575)涨5.2% 上市两周股价翻倍 吡洛西利一线治疗临床III期展现出良好的疗效性","url":"https://stock-news.laohu8.com/highlight/detail?id=2578304660","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578304660?lang=zh_cn&edition=fundamental","pubTime":"2025-10-27 10:47","pubTimestamp":1761533275,"startTime":"0","endTime":"0","summary":"金吾财讯 | 轩竹生物-B(02575)再起升势，截至发稿，涨5.2%，报62.7港元，成交额2055万港元。需要注意的是该股于10月16日盘中最低点23.82港元至今日涨幅超1.6倍。消息面上，日前，2025年欧洲肿瘤内科学会(ESMO)年会正式召开。作为全球最具学术影响力的肿瘤学盛会之一，ESMO向来是创新药企业披露核心品种重磅临床数据的重要平台，各大药企借此不仅能提升自身知名度与行业影响力，更可拓展合作机遇。港股上市仅两周的轩竹生物，此次便在ESMO大会披露吡洛西利一线治疗临床III期(BRIGHT-3)研究数据，展现出良好的疗效性和安全优势。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1968487","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","02575","BK4134"],"gpt_icon":0},{"id":"2578638381","title":"四环医药走出阵痛","url":"https://stock-news.laohu8.com/highlight/detail?id=2578638381","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578638381?lang=zh_cn&edition=fundamental","pubTime":"2025-10-26 12:05","pubTimestamp":1761451500,"startTime":"0","endTime":"0","summary":"四环医药似乎正在走出阵痛。2020年，四环医药正式宣布，业务将从以仿制药为主，转型至以医美和创新药为主。2025年上半年，四环医药在连续三年亏损后首次扭亏，盈利1.03亿元。医美业务贡献了超3亿元利润，成为最大的利润来源。在半年报中，四环医药再次强调了医美“核心增长引擎”的战略地位。医美营收追平头部企业对现在的四环医药来说，医美毫无疑问已是扛大旗的业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251026134153a6ce6f25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251026134153a6ce6f25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","00460","BK1191","BK1600","02575","BK1593"],"gpt_icon":0},{"id":"2578637549","title":"医药生物行业跟踪周报：2025ESMO中国之声闪耀全球 PD1双抗与ADC成为全球焦点","url":"https://stock-news.laohu8.com/highlight/detail?id=2578637549","media":"东吴证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578637549?lang=zh_cn&edition=fundamental","pubTime":"2025-10-26 00:00","pubTimestamp":1761408000,"startTime":"0","endTime":"0","summary":"勃林格殷格翰first-in-class 肺纤维化疗法在华获批上市；诺华“司库奇尤单抗”治疗风湿性多肌痛III 期研究成功。10 月22 日，勃林格殷格翰宣布那米司特片获国家药监局批准上市，用于治疗成人特发性肺纤维化。10 月22 日，诺华宣布，司库奇尤单抗在III 期REPLENISH 研究中达到了主要终点及所有次要终点 。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510262026369743064c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510262026369743064c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","02228","02575","BK1574","BK1141","06160","BK1617","BK1161","BK1515","09939"],"gpt_icon":0},{"id":"1110501310","title":"一周港股牛熊榜 | 周内飙升75%！次新股轩竹生物上市累升逾400%；老铺黄金、泡泡玛特周跌超16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110501310","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110501310?lang=zh_cn&edition=fundamental","pubTime":"2025-10-24 17:34","pubTimestamp":1761298484,"startTime":"0","endTime":"0","summary":"10月15日，优必选宣布与某知名上市汽车科技公司正式签署人形机器人采购合同，订单金额超3200万元。值得注意的是，10月17日，老铺黄金发布预告，公司将于10月26日进行产品价格调整。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"一周港股牛熊榜 | 周内飙升75%！次新股轩竹生物上市累升逾400%；老铺黄金、泡泡玛特周跌超16%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09880","01635","03677","01651","09966","01729","09992","02575","00412","06181"],"gpt_icon":1},{"id":"2577593543","title":"轩竹生物-B10月24日主力净流入124.5万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2577593543","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577593543?lang=zh_cn&edition=fundamental","pubTime":"2025-10-24 16:15","pubTimestamp":1761293719,"startTime":"0","endTime":"0","summary":"10月24日, 轩竹生物-B股价涨0.17%，报收59.60元，成交金额4627.4万元，换手率0.49%，振幅12.69%，量比0.25。轩竹生物-B今日主力资金净流入124.5万元，上一交易日主力净流出286.4万元。该股近5个交易日上涨75.81%，主力资金累计净流入4016.8万元；近20日主力资金累计净流入5873.2万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102416160597400a81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102416160597400a81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0},{"id":"2577379228","title":"大涨456%！创新药万绿丛中，这家“独红”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2577379228","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577379228?lang=zh_cn&edition=fundamental","pubTime":"2025-10-23 16:08","pubTimestamp":1761206887,"startTime":"0","endTime":"0","summary":"万“绿”丛中一点“红”。这样的背景下，这家仅上市7个交易日、股价大涨456%的Biotech显得难能可贵。近日，轩竹生物在港交所上市，每股发售价11.6港元，开盘即涨153.97%至29.46港元，截至10月23日，最高价已飙升至64.5港元，涨幅高达456%。吡洛西利组的ORR高达63.5%，而对照组仅为42.5%。轩竹生物研发的抗肿瘤1类新药地罗阿克片于2025年8月获得国家药监局批准上市，主要用于ALK阳性晚期非小细胞肺癌的一线治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023161441a4702e12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023161441a4702e12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02575","06978","BK1161"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":70,"code":"91000000","status":"200"}]}}